The proposed rule could “weaken the NIH’s benign influence over research risks,” writes Doni Bloomfield.
Source: STAT News
Opinion: How a controversial rule could hurt the NIH’s ability to manage risk
You may also like
Insurers Hedge on Trump-Backed Pledge To Improve...
Violence Repeatedly Erupts at Dementia Care Facilities...
Leadership Vacuum: Agencies in New York and Beyond...
A Deloitte-Run System Denied Medicaid Benefits for...
Severely Ill Prisoners Granted Early Release Are Left...
Tempus to buy cancer test maker Personalis for $1.5B
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.